Segment Information

6 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Segment Information

12. Segment Information

Segment revenue, operating income (loss), and depreciation and amortization were as follows:

	Three Months Ended March 31,						Six Months Ended March 31,
(In thousands)	2024			2023			2024			2023
Revenue:
Medical Device	$	24,826		$	19,707		$	48,371		$	38,725
In Vitro Diagnostics		7,132			7,491			14,139			13,406
Total revenue	$	31,958		$	27,198		$	62,510		$	52,131
Operating income (loss):
Medical Device	$	302		$	(7,059	)	$	78		$	(14,294	)
In Vitro Diagnostics		3,356			3,636			6,480			6,584
Total segment operating income (loss)		3,658			(3,423	)		6,558			(7,710	)
Corporate		(2,999	)		(3,160	)		(6,221	)		(6,102	)
Total operating income (loss)	$	659		$	(6,583	)	$	337		$	(13,812	)
Depreciation and amortization:
Medical Device	$	1,916		$	1,933		$	3,970		$	3,886
In Vitro Diagnostics		96			75			193			152
Corporate		84			84			266			176
Total depreciation and amortization	$	2,096		$	2,092		$	4,429		$	4,214

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.